Mumbai, July 14, 2017: Pahrma Major, Jubilant Life Sciences today said its subsidiary has received an abbreviated new drug application (ANDA) final approval for Bupropion Hydro chloride extended-release tablets USP (XL), 150 mg and 300 mg. Bupropion Hydro chloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal effective disorder,company said in a filing with BSE. The approved product is the generic version of Well but rin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal effective disorder. This is the fourth approval received by the company from the USFDA during the current financial year. As on March 31, 2017, Jubilant Life Sciences had 81 ANDAs for oral solids filed in the US, of which 51 have been approved, the filing added.
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…